Lipoprotein-based drug delivery.

Lipoprotein-based drug delivery.
复制标题

基于脂蛋白的药物递送。

DOI:
10.1016/j.addr.2020.08.003
复制
发表时间:
2020
影响因子:
16.1
通讯作者:
Wolfram J
Wolfram J
中科院分区:
医学1区
文献类型:
--
作者:
Busatto S;Walker SA;Grayson W;Pham A;Tian M;Nesto N;Barklund J;Wolfram J

文献摘要

参考文献

被引文献

相似文献

脂蛋白(LPs)是由肝脏和肠道产生的非均匀纳米颗粒。脂多糖在膳食和内源性脂质通过细胞膜受体或细胞表面结合脂蛋白脂肪酶转运到靶细胞中起主要作用。脂多糖的稳定性、生物相容性和选择性运输使其成为各种治疗和显像剂的有希望的递送载体。本文综述了基于lp的药物递送的分离、制造和药物装载技术,以及最近在癌症、动脉粥样硬化和其他危及生命的疾病的诊断和治疗中的应用。
Lipoproteins (LPs) are circulating heterogeneous nanoparticles produced by the liver and intestines. LPs play a major role in the transport of dietary and endogenous lipids to target cells through cell membrane receptors or cell surface-bound lipoprotein lipase. The stability, biocompatibility, and selective transport of LPs make them promising delivery vehicles for various therapeutic and imaging agents. This review discusses isolation, manufacturing, and drug loading techniques used for LP-based drug delivery, as well as recent applications for diagnosis and treatment of cancer, atherosclerosis, and other life-threatening diseases.
肽和蛋白质产生的化学方法。
DOI: 10.3390/molecules18044373
发表时间: 2013-04-12
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者:
Chandrudu S;Simerska P;Toth I
通讯作者: Toth I
DOI: 10.1021/bc100083d
发表时间: 2010-06-16
影响因子: 4.7
作者:
Fischer NO;Infante E;Ishikawa T;Blanchette CD;Bourne N;Hoeprich PD;Mason PW
通讯作者: Mason PW
DOI: 10.1161/circulationaha.116.025687
发表时间: 2016-12-13
期刊: Circulation
影响因子: 37.8
作者:
Michael Gibson C;Korjian S;Tricoci P;Daaboul Y;Yee M;Jain P;Alexander JH;Steg PG;Lincoff AM;Kastelein JJ;Mehran R;D'Andrea DM;Deckelbaum LI;Merkely B;Zarebinski M;Ophuis TO;Harrington RA
通讯作者: Harrington RA
DOI: 10.1016/j.abb.2008.02.036
发表时间: 2008-05-01
影响因子: 3.9
作者:
Arrese, Estela L.;Rivera, Laticia;Soulages, Jose L.
通讯作者: Soulages, Jose L.
DOI: 10.1039/c9bm01007f
发表时间: 2020-01-01
影响因子: 6.6
作者:
Busatto, S.;Zendrini, A.;Bergese, P.
通讯作者: Bergese, P.